VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.7 USD | +0.78% |
|
-1.05% | +4.62% |
| May. 08 | Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 25 | Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.15B |
|---|---|---|---|---|---|
| Net income 2024 * | -452M | Net income 2025 * | -507M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-16.4
x | P/E ratio 2025 * |
-15.1
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | +0.78% | ||
| 1 week | -1.05% | ||
| Current month | +8.51% | ||
| 1 month | +6.17% | ||
| 3 months | -11.11% | ||
| 6 months | +35.69% | ||
| Current year | +4.62% |
1 week
63.63
68.22
1 month
58.1068.22
Current year
53.8382.04
1 year
44.2082.04
3 years
16.7882.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director of Finance/CFO | 55 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Anne Drapeau
BRD | Director/Board Member | 57 | 21-09-15 |
Heath Lukatch
BRD | Director/Board Member | 56 | 18-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 65.7 | +0.78% | 491,979 |
| 24-05-10 | 65.19 | -0.58% | 533,487 |
| 24-05-09 | 65.57 | -1.83% | 919,834 |
| 24-05-08 | 66.79 | -1.08% | 467,870 |
| 24-05-07 | 67.52 | +1.69% | 556,995 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
65.7
USD
Average target price
103.1
USD
Spread / Average Target
+56.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.62% | 7.15B | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -0.38% | 21.93B | |
| -12.15% | 22.34B | |
| -7.66% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- PCVX Stock